24/7 Market News Snapshot 01 May, 2025 – Adial Pharmaceuticals, Inc (NASDAQ:ADIL)

May 1, 2025

DENVER, Colo., 01 May, 2025 (www.247marketnews.com) – (NASDAQ:ADIL) are discussed in this article.
Adial Pharmaceuticals, Inc. has experienced a significant rise in its stock value, opening at $0.70 and soaring to $1.059, marking a remarkable increase of 53.48%. This surge follows a prior close of $0.690, reflecting growing investor confidence and interest, with trading volumes reaching an impressive 2.92 million shares. Such robust market activity suggests the potential for a bullish trend, possibly attracting additional investors as the company charts its upward course.

In conjunction with the stock performance, Adial Pharmaceuticals recently announced the issuance of U.S. Patent No. 12,274,692, granted on April 15, 2025. This patent encompasses a groundbreaking method for treating alcohol-related diseases and opioid-related disorders using its investigational drug, AD04. The innovative approach is designed for genetically identified patients, enhancing the company’s commitment to personalized medicine.

The newly secured patent fortifies Adial’s intellectual property portfolio by detailing a precision treatment strategy. This strategy capitalizes on specific serotonin-related gene variations, including HTR3A, HTR3B, and SLC6A4, thereby aligning pharmacological responses with genetic markers. Cary Claiborne, the company’s Chief Executive Officer, emphasized that this patent represents a pivotal achievement in their mission to provide customized therapies for those struggling with alcohol use disorder and opioid dependence.

Currently, AD04 is undergoing crucial Phase 3 clinical trials as part of the ONWARD™ study, which has shown promising preliminary results in mitigating heavy drinking among genetically predisposed individuals. Furthermore, the research suggests potential applications for AD04 in addressing other addiction-related challenges, including opioid use disorder, gambling addiction, and obesity. Adial Pharmaceuticals remains dedicated to leading advancements in treatment options for addiction, positioning itself at the forefront of innovation in this critical area of healthcare.

Related news for (ADIL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.